[1] |
REDAELLI S, PLAZA-MENACHO I, MOLOGNI L. Novel targeted therapeutics for MEN2[J]. Endocr Relat Cancer, 2018, 25(2):T53-68. DOI: 10.1530/ERC-17-0297.
|
[2] |
GUERIN C, ROMANET P, TAIEB D,et al. Looking beyond the thyroid:advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms[J]. Endocr Relat Cancer, 2018, 25(2):T15-28. DOI: 10.1530/ERC-17-0266.
|
[3] |
MCDONNELL J E, GILD M L, CLIFTON-BLIGH R J,et al. Multiple endocrine neoplasia:an update[J]. Intern Med J, 2019, 49(8):954-961. DOI: 10.1111/imj.14394.
|
[4] |
|
[5] |
WELLS S A Jr, ASA S L, DRALLE H,et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610. DOI: 10.1089/thy.2014.0335.
|
[6] |
WANG Y P, LI F P, WANG H H,et al. Impact of RET screening on the management of multiple endocrine neoplasia type 2A:10 years experience and follow-up in three families[J]. Endocr Metab Immune Disord Drug Targets, 2022, 22(3):339-347. DOI: 10.2174/2214083203666210826094602.
|
[7] |
BREZA J Jr, SR J B. Multiple endocrine neoplasia 2A(MEN 2A) syndrome[J]. Bratisl Lek Listy, 2018, 119(2):120-125. DOI: 10.4149/BLL_2018_034.
|
[8] |
SARAVANA-BAWAN B, PASTERNAK J D. Multiple endocrine neoplasia 2:an overview[J]. Ther Adv Chronic Dis, 2022. DOI: 10.1177/20406223221079246.
|
[9] |
KIERNAN C M, GRUBBS E G. Surgical management of multiple endocrine neoplasia 1 and multiple endocrine neoplasia 2[J]. Surg Clin North Am, 2019, 99(4):693-709. DOI: 10.1016/j.suc.2019.04.015.
|
[10] |
郭敏,薛铮,药红梅,等. 误诊为心肌炎的多发性内分泌腺瘤2型一例[J]. 中华心血管病杂志,2021(2):182-184.
|
[11] |
METE O, ESSA A, BRAMDEV A,et al. MEN2 syndrome-related medullary thyroid carcinoma with focal tyrosine hydroxylase expression:does it represent a hybrid cellular phenotype or functional state of tumor cells? [J]. Endocr Pathol, 2017, 28(4):362-366. DOI: 10.1007/s12022-017-9485-4.
|
[12] |
QI X P, ZHAO J Q, FANG X D,et al. Spectrum of germline RET variants identified by targeted sequencing and associated multiple endocrine neoplasia type 2 susceptibility in China[J]. BMC Cancer, 2021, 21(1):369. DOI: 10.1186/s12885-021-08116-9.
|
[13] |
LEE J Y, KIM S Y, JO K H,et al. Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2(MEN2)[J]. Korean J Intern Med, 2022, 37(2):398-410. DOI: 10.3904/kjim.2021.311.
|
[14] |
FEBRERO B, RODRÍGUEZ J M, RÍOS A,et al. Prophylactic thyroidectomy in multiple endocrine neoplasia 2(MEN2) patients with the C634Y mutation:a long-term follow-up in a large single-center cohort[J]. Eur J Surg Oncol, 2019, 45(4):625-630. DOI: 10.1016/j.ejso.2018.09.002.
|
[15] |
OSPINA N S, MARAKA S, DONEGAN D,et al. Clinical features of a family with multiple endocrine neoplasia type 2A caused by the D631Y RET mutation[J]. Thyroid, 2017, 27(10):1332-1334. DOI: 10.1089/thy.2016.0536.
|
[16] |
SIQUEIRA D R, CEOLIN L, FERREIRA C V,et al. Role of RET genetic variants in MEN2-associated pheochromocytoma[J]. Eur J Endocrinol, 2014, 170(6):821-828. DOI: 10.1530/EJE-14-0084.
|
[17] |
WEBER T, POPLAWSKI A, VORLÄNDER C,et al. Preoperative calcitonin testing improves the diagnosis of medullary thyroid carcinoma in female and male patients[J]. Eur J Endocrinol, 2022, 186(2):223-231. DOI: 10.1530/EJE-21-1015.
|
[18] |
LI Y, TAN Y Q, TANG Z X,et al. Multiple endocrine neoplasia 2A with RET mutation p.Cys611Tyr:a case report[J]. Medicine(Baltimore), 2021, 100(22):e26230. DOI: 10.1097/MD.0000000000026230.
|
[19] |
ILANCHEZHIAN M, KHAN S, OKAFOR C,et al. Update on the treatment of medullary thyroid carcinoma in patients with multiple endocrine neoplasia type 2[J]. Horm Metab, 2020, 52(8):588-597. DOI: 10.1055/a-1145-8479.
|
[20] |
MUCHA L, LEIDIG-BRUCKNER G, FRANK-RAUE K,et al. Phaeochromocytoma in multiple endocrine neoplasia type 2:RET Codon-specific penetrance and changes in management during the last four decades[J]. Clin Endocrinol(Oxf), 2017, 87(4):320-326. DOI: 10.1111/cen.13386.
|
[21] |
OHSUGI H, TAKIZAWA N, KINOSHITA H,et al. Pheochromocytoma arising from an ectopic adrenal tissue in multiple endocrine neoplasia type 2A[J]. Endocrinol Diabetes Metab Case Rep, 2019, 2019:EDM190073. DOI: 10.1530/EDM-19-0073.
|
[22] |
PAL R, RASTOGI A, KUMAR S,et al. Metastatic pheochromocytoma in MEN 2A:a rare association[J]. BMJ Case Rep, 2018, 2018:bcr-2017-222758. DOI: 10.1136/bcr-2017-222758.
|
[23] |
IGLESIAS P, SANTACRUZ E, GARCÍA-SANCHO P,et al. Pheochromocytoma:a three-decade clinical experience in a multicenter study[J]. Rev Clin Esp(Barc), 2021, 221(1):18-25. DOI: 10.1016/j.rceng.2019.12.011.
|
[24] |
MIYATA Y, HATANO K, OKUNO Y,et al. Laparoscopic resection of aortocaval paraganglioma diagnosed by serial increase in urinary metanephrines after bilateral adrenalectomy in a patient with multiple endocrine neoplasia type 2A[J]. IJU Case Rep, 2021, 4(6):347-350. DOI: 10.1002/iju5.12345.
|
[25] |
KUMAR S, LILA A R, MEMON S S,et al. Metastatic cluster 2-related pheochromocytoma/paraganglioma:a single-center experience and systematic review[J]. Endocr Connect, 2021, 10(11):1463-1476. DOI: 10.1530/EC-21-0455.
|
[26] |
HU X F, GUAN J, WANG Y D,et al. A narrative review of multiple endocrine neoplasia syndromes:genetics,clinical features,imaging findings,and diagnosis[J]. Ann Transl Med, 2021, 9(11):944. DOI: 10.21037/atm-21-1165.
|
[27] |
ROMEI C, CIAMPI R, ELISEI R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma[J]. Nat Rev Endocrinol, 2016, 12(4):192-202. DOI: 10.1038/nrendo.2016.11.
|